Phenyl 4-(2-oxopyrrolidin-1-yl)benzenesulfonates and phenyl 4-(2-oxopyrrolidin-1-yl)benzenesulfonamides as new antimicrotubule agents targeting the colchicine-binding site

Auteur(s): Gagné-Boulet, MathieuBouzriba, ChahrazedChavez Alvarez, Atziri CorinFortin, Sébastien
Résumé: We recently designed and prepared new families of potent antimicrotubule agents designated as N-phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB–SOs) and phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides (PIB–SAs). Our previous structure-activity relationship studies (SAR) focused on the aromatic ring B of PIB-SOs and PIB-SAs leaving the impact of the phenylimidazolidin-2-one moiety (ring A) on the binding to the colchicine-binding site (C-BS) poorly studied. Therefore, the aim of the present study was to evaluate the effect of replacing the imidazolidin-2-one (IMZ) group by a pyrrolidin-2-one moiety. To that end, 15 new phenyl 4-(2-oxopyrrolidin-1-yl)benzenesulfonate (PYB–SO) and 15 phenyl 4-(2-oxopyrrolidin-1-yl)benzenesulfonamide (PYB-SA) derivatives were designed, prepared, chemically characterised and biologically evaluated. PYB-SOs and PYB-SAs exhibit antiproliferative activity in the low nanomolar to low micromolar range (0.0087–8.6 μM and 0.056–21 μM, respectively) on human HT-1080, HT-29, M21 and MCF7 cancer cell lines. Moreover, they block cell cycle progression in G2/M phase. Immunofluorescence, tubulin affinity and tubulin polymerisation assays show that they cause microtubule depolymerisation by docking the C-BS. In addition, docking assays with the most potent derivatives show binding affinity toward the C-BS and they also exhibit weak or no toxicity toward chick embryos. Finally, physicochemical properties calculated using the SwissADME algorithm show that PYB-SOs and PYB-SAs are promising new families of antimicrotubule agents.
Type de document: Article de recherche
Date de publication: 5 mars 2021
Date de la mise en libre accès: 5 mars 2023
Version du document: AM
Licence Creative Commons: https://creativecommons.org/licenses/by-nc-nd/4.0
Lien permanent: http://hdl.handle.net/20.500.11794/74062
Ce document a été publié dans: European journal of medicinal chemistry, Vol. 213, 113136 (2021)
https://doi.org/10.1016/j.ejmech.2020.113136
Elsevier
Autre version disponible: 10.1016/j.ejmech.2020.113136
33472119
Collection :Articles publiés dans des revues avec comité de lecture

Fichier(s) :
Description TailleFormat 
35. European Journal of Medicinal Chemistry 2021.pdf
2.58 MBAdobe PDF    Demander une copie
Tous les documents dans CorpusUL sont protégés par la Loi sur le droit d'auteur du Canada.